Centre Hospitalier Universitaire De Toulouse
- Address
- lock Available on a paid plan
Neoplasms Research at Centre Hospitalier Universitaire De Toulouse
Clinical research in the Service Pneumologie focuses strongly on cancer, especially non-small cell lung cancer and small cell lung cancer. These studies are designed to evaluate new treatment strategies, compare them with current standards, and better understand how to improve survival for people with advanced lung tumors.
- Studies in non-small cell lung cancer are assessing maintenance treatment approaches and combination therapies to improve disease control.
- Research in small cell lung cancer is comparing novel options with standard care to extend overall survival.
- Several trials are aimed at testing whether newer immunotherapy-based approaches can slow cancer progression more effectively.
This work highlights the site’s active role in advancing oncology care through trials that seek to refine treatment effectiveness and support better outcomes for patients.
Immune System Diseases Research
Alongside oncology, the site also conducts studies in immune system diseases, with a focus on hidradenitis suppurativa. This research is centered on evaluating new therapies that may reduce symptoms, improve disease control, and offer more effective options for patients living with this chronic inflammatory condition.
- Trials in hidradenitis suppurativa are examining whether emerging treatments can improve both effectiveness and safety.
- The research aims to support better management of a painful, long-term inflammatory skin disease.
These studies show that Centre Hospitalier Universitaire De Toulouse is contributing not only to cancer research but also to the development of improved treatments for complex inflammatory disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Toulouse
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Apr 2021 | Oct 2024 |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 2 | Unknown | 2022-05-02 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.